Date: 2017-06-13
Type of information: Company acquisition
Acquired company: Alphora Research (Canada)
Acquiring company: Eurofins Scientific (Luxembourg)
Amount: undisclosed
Terms:
- • On June 13, 2017, Eurofins Scientific, a world leader in biopharmaceutical testing, announced the acquisition of Alphora Research, a full service contract research, development and manufacturing organization for complex and niche small molecule active pharmaceutical ingredients (API), based in Mississauga, Ontario, Canada.
- Alphora’s expertise in API development, testing and manufacturing provides Eurofins entry into the dynamic and growing CRDMO market. It is uniquely positioned to capitalize on the strong growth and positive trends in the API industry, which are driven by the increasing importance of outsourcing in biopharmaceutical R&D, limited API manufacturing capacity in North America, and increased funding for early stage discovery and development. Furthermore, Alphora is ideally positioned to support the development of discovery candidates that emerge from Eurofins’ extensive drug discovery platform. In addition to Eurofins’ existing capabilities in preclinical, clinical, and GMP product testing, this acquisition of Alphora further strengthens the Group’s highly compelling and integrated offering to enable clients to progress through the entire drug development process.
Details:
- Alphora Research is a full service contract research, development and manufacturing organization (CRDMO) for complex and niche small molecule active pharmaceutical ingredients. The company has extensive capabilities in multi-step syntheses, as well as the development of cytotoxic and highly potent APIs. It operates two fully integrated facilities to address a wide array of API challenges, providing a full spectrum of complex API development, testing and manufacturing services.
- As such the company supports biopharmaceutical companies from the preclinical phase through to commercialization of niche products, and is an ideal complement to Eurofins’ discovery and other biopharmaceutical testing activities. Alphora has been founded in 2003, and expects to generate revenues in excess of CAD 30m in 2017, with organic growth and EBITDA margin well above Eurofins’ objectives.
Related: Technology - Services
Is general: Yes
